Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition.

The syndrome of heart failure has traditionally been viewed as a functional disorder precipitated by impaired left ventricular pump performance. The classification into systolic and diastolic dysfunction has emphasized the functional distinction between abnormalities in contraction and relaxation. Recently, however, attention has been directed toward the possibility that the systolic dysfunction, which has been thought to be related to contractile failure, could be a consequence of a structural increase in ventricular chamber volume. This construct would revise the conventional view—contractile failure leads to chamber dilatation—with a more anatomic basis for heart failure: Chamber dilatation occurs as an early response that results in the reduced wall motion that is mandated to generate a normal stroke volume from a large ventricular end-diastolic volume. This structural alteration is not necessarily related to the underlying etiological cardiac pathology but rather represents an intrinsic morphological change that progresses over time in response to an initiating event. The term “remodeling” often is used to address these structural changes and may be best defined as a change in chamber volume and shape not related to a preload-mediated increase in sarcomere length. In this issue of Circulation , Greenberg and his SOLVD colleagues1 revisit the remodeling issue in chronic heart failure with echocardiographic data collected in the long-term trial of enalapril versus placebo in both symptomatic and asymptomatic patients with left ventricular remodeling. Patients were selected for this study on the basis of an ejection fraction of ≤35%. At the time the study was designed, this low ejection fraction was defined as systolic dysfunction. The implication of that designation is that an impairment of myocardial shortening was the primary abnormality. A more contemporary hypothesis, based on the concept of left ventricular remodeling, is that the low ejection fraction reflects in part a primary increase in chamber volume …

[1]  J. Cohn,et al.  Prognostic Significance of Serial Changes in Left Ventricular Ejection Fraction in Patients With Congestive Heart Failure , 1993, Circulation.

[2]  F. Tristani,et al.  Ejection Fraction, Peak Exercise Oxygen Consumption, Cardiothoracic Ratio, Ventricular Arrhythmias, and Plasma Norepinephrine as Determinants of Prognosis in Heart Failure , 1993, Circulation.

[3]  M. Daemen,et al.  Angiotensin II Receptor Blockade After Myocardial Infarction in Rats: Effects on Hemodynamics, Myocardial DNA Synthesis, and Interstitial Collagen Content , 1992, Journal of cardiovascular pharmacology.

[4]  J. Cohn,et al.  Plasma Norepinephrine, Plasma Renin Activity, and Congestive Heart Failure Relations to Survival and the Effects of Therapy in V‐HeFT II , 1993, Circulation.

[5]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure , 1986 .

[6]  J. Cohn,et al.  Angiotensin-converting enzyme inhibition and beta-adrenoceptor blockade regress established ventricular remodeling in a canine model of discrete myocardial damage. , 1994, Journal of the American College of Cardiology.

[7]  J. Cohn Vasodilator Therapy for Heart Failure: The Influence of Impedance on Left Ventricular Performance , 1973, Circulation.

[8]  B. Magnani,et al.  The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction , 1995 .

[9]  G. Murray,et al.  Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators , 1993 .

[10]  J. Cohn,et al.  Role of the Renin-Angiotensin System in the Systemic Vasoconstriction of Chronic Congestive Heart Failure , 1978, Circulation.

[11]  W. Linz,et al.  A specific B2‐bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril , 1992, British journal of pharmacology.

[12]  J. A. Snow,et al.  Chronic vasodilator therapy in the management of cardiogenic shock and intractable left ventricular failure. , 1974, Annals of internal medicine.

[13]  J. Ross,et al.  Oxygen consumption of the heart. Newer concepts of its multifactoral determination. , 1968, The American journal of cardiology.

[14]  M. Quiñones,et al.  Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. , 1995, Circulation.

[15]  B. Jugdutt,et al.  Effect of long-term captopril therapy on left ventricular remodeling and function during healing of canine myocardial infarction. , 1992, Journal of the American College of Cardiology.

[16]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[17]  G. Lamas,et al.  Quantitative Two-Dimensional Echocardiographic Measurements are Major Predictors of Adverse Cardiovascular Events After Acute Myocardial Infarction: The Protective Effect of Captopril , 1994, Circulation.

[18]  G. Lamas,et al.  Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. , 1988, The New England journal of medicine.

[19]  K. Uğurbil,et al.  Myocardial bioenergetic abnormalities in a canine model of left ventricular dysfunction. , 1994, Journal of the American College of Cardiology.

[20]  K. Swedberg,et al.  Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) , 1992, The New England journal of medicine.

[21]  F. Tristani,et al.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.

[22]  S. Yusuf,et al.  Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. , 1992, Circulation.

[23]  J. Cohn,et al.  Long-term oral nitrate therapy prevents chronic ventricular remodeling in the dog. , 1993, Journal of the American College of Cardiology.

[24]  O. Carretero,et al.  Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. , 1993, Circulation research.

[25]  T. Parrish,et al.  Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. , 1995, Circulation.

[26]  J. Cohn,et al.  Myocardial damage after repetitive direct current shock in the dog: correlation between left ventricular end-diastolic pressure and extent of myocardial necrosis. , 1978, The Journal of laboratory and clinical medicine.

[27]  W. Linz,et al.  Role of angiotensin II receptor antagonism and converting enzyme inhibition in the progression and regression of cardiac hypertrophy in rats. , 1991, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[28]  J. Cohn,et al.  Relative Effects of α1‐Adrenoceptor Blockade, Converting Enzyme Inhibitor Therapy, and Angiotensin II Subtype 1 Receptor Blockade on Ventricular Remodeling in the Dog , 1994, Circulation.

[29]  J. Cohn,et al.  Hemodynamic, left ventricular structural and hormonal changes after discrete myocardial damage in the dog. , 1992, Journal of the American College of Cardiology.